Peptide science, written plainly
Original articles on synthesis, storage, quality testing and receptor pharmacology — for researchers and professionals evaluating compounds and suppliers.
New Research Links NAD+ Metabolic Dysfunction to Immune Cell Aging in Colitis
A newly published study traces a specific chain of events — NAD+ dysregulation, leaking mitochondrial DNA, and an inflammatory signaling cascade — that drives immune cells into a senescent, disease-worsening state in ulcerative colitis. Here's what the findings actually show.
Sep 10, 2026A Case Report Links Semaglutide to Improvement in Post-Vaccination Dysautonomia
A single-patient case report in Immunopharmacology and Immunotoxicology found substantial reductions in autonomic symptom scores after semaglutide treatment for post-vaccination dysautonomia — an early signal, not a validated indication.
Sep 9, 2026GLP-1 Receptor Agonists vs. MRAs in Resistant Hypertension: What a New Cohort Study Found
Mineralocorticoid receptor antagonists are the guideline-recommended fourth-line drug for resistant hypertension, but a new 213,000-patient cohort study asks whether GLP-1 receptor agonists might belong in that conversation too.
Sep 8, 2026A MOTS-C Hydrogel for Mitochondrial Transplantation After Heart Attack
Isolated mitochondria used for transplant therapy typically lose function within hours. Researchers built a MOTS-C-based hydrogel that extends their viability and reprograms macrophage metabolism, reducing cardiac damage in a rat heart-attack model.
Sep 6, 2026A Case Report Links Rapid Semaglutide-Associated Weight Loss to an Uncommon Ear Condition
A 79-year-old man lost roughly 200 pounds after starting semaglutide and later developed an unusual ear condition tied to loss of the fatty tissue that normally keeps the Eustachian tube closed. Here's what the case report describes and what it does and doesn't tell researchers.
Sep 6, 2026Mouse Study Traces GIP Receptor Effects on Appetite to Two Distinct Brain Regions
Adding a GIP receptor agonist or a GIP receptor antagonist to GLP-1 therapy both increase weight loss — a paradox that has puzzled researchers. A new mouse study locates the two effects in different brain regions, offering a mechanistic explanation.
Sep 4, 2026MOTS-c and Sepsis-Induced Cardiomyopathy: A New Review Weighs the Mechanistic Case
A late-August review asks whether MOTS-c's AMPK and mitochondrial-quality-control effects are relevant to sepsis-induced cardiomyopathy. The authors' answer is careful: plausible, but not yet demonstrated in the condition itself.
Aug 31, 2026A Case Report on Online-Sourced Retatrutide Complicating Care in Type 1 Diabetes
A newly published case report from a UK acute medicine unit describes a type 1 diabetes patient whose illness was complicated after self-administering online-sourced retatrutide. The case is a concrete illustration of why sourcing, purity, and clinical oversight matter for any investigational peptide.
Aug 30, 2026CagriSema and Anthropometric Treatment Targets: A New Look at REDEFINE 1
Most obesity trials report results as percentage weight loss. A new post hoc analysis of REDEFINE 1 instead asks how many participants crossed absolute BMI and waist-to-height ratio thresholds — and finds CagriSema pulled meaningfully more participants across that line than semaglutide, cagrilintide, or placebo.
Aug 29, 2026New Rat Study: BPC-157 Counteracts Gentamicin-Induced Kidney Injury
A newly published rat study from BPC-157's original discovery group finds the peptide counteracts severe gentamicin-induced kidney injury, using a three-arm nitric oxide-agent design to probe how that protection relates to the NO system — extending BPC-157's research base into a new organ system.
Aug 26, 2026A Penn Study Finds a Midbrain Site Where GLP-1 and Amylin Signals Add Together
A rat study in Physiology & Behavior maps GLP-1 and amylin receptor signaling onto two mostly non-overlapping neuron populations in the laterodorsal tegmental nucleus, and finds that engaging both at once reduces food intake and the effort animals will expend for a palatable reward.
Aug 25, 2026A UCLA Scoping Review Maps the Evidence Base for Six Recovery Peptides
Researchers at UCLA screened the published literature on six peptides commonly discussed for recovery and performance. Roughly two-thirds of what they found was animal work, and the small human literature was heterogeneous and largely uncontrolled.
Aug 23, 2026MOTS-c Identified as a Mitochondrial-Encoded Host Defense Peptide
MOTS-c has been studied almost entirely as a metabolic signalling peptide. A new eLife paper argues it is also an antimicrobial and immune-programming peptide — and the first one known to be encoded in mitochondrial DNA.
Aug 21, 2026KPV and Fat-Cell Differentiation: A New Direction for a Familiar Tripeptide
Nearly all published work on KPV sits in the inflammation literature. A new preclinical paper looks somewhere the tripeptide hasn't been studied before: the process by which preadipocytes become fat cells.
Aug 15, 2026Amylin Analogs and the Tolerability Question
Most coverage of obesity pharmacology tracks a single number: how much weight a compound produces. A review published this month argues that for amylin-based agents, whether reduced food intake reflects normal satiation or something closer to malaise is an equally important — and mechanistically tractable — question.
Aug 14, 2026Lower Circulating MOTS-c Found in Hashimoto's Thyroiditis, New Study Reports
A newly published cross-sectional study finds that people with Hashimoto's thyroiditis carry significantly lower circulating MOTS-c than matched controls, and that the deficit correlates with insulin resistance and autoantibody burden — a human clinical data point for a peptide whose literature has so far been dominated by rodent work.
Aug 13, 2026STEP 12: Semaglutide 2.4 mg in Chinese and Taiwanese Adults with Overweight or Obesity
Most of the semaglutide weight-management evidence base comes from trials run in North America and Europe using WHO-standard BMI cutoffs. STEP 12, published this month, is the first placebo-controlled STEP trial conducted in mainland China and Taiwan using locally defined BMI thresholds — here's what it found.
Aug 11, 2026REIMAGINE 1: Placebo-Controlled Phase 3 Data on CagriSema in Early Type 2 Diabetes
REIMAGINE 1, a 189-participant phase 3a trial published this month, is the first placebo-controlled read on CagriSema in people with early-stage type 2 diabetes not yet on background metformin. Here's what the trial measured and how it complements the REIMAGINE 2 data covered here previously.
Aug 10, 2026New Research: BPC-157 and TB-500 Aid Tendon Repair in Rats — but Combining Them Adds Nothing
A newly published rat study directly tests a question this site's own product notes raise but don't answer: does combining BPC-157 with TB-500 produce a better tendon-repair outcome than either peptide alone? The biomechanical data say no — and TB-500 alone came out looking like the stronger single agent.
Aug 7, 2026A Sports Medicine Review Weighs the Evidence on BPC-157 and TB-500
A newly published review in the journal Sports Medicine takes stock of the peptides circulating in injury-recovery and performance research, including BPC-157 and TB-500. Its central message: preclinical results are often encouraging, but rigorous human safety data remain thin.
Aug 6, 2026New Research: MOTS-C Suppresses Cardiac and Systemic Inflammasome Activity in a Diabetic Rat Model
A newly published rat study links MOTS-C to reduced inflammasome activity in both the bloodstream and heart tissue, adding a cardiovascular-inflammation angle to the peptide's established metabolic research profile.
Aug 6, 2026A Head-to-Head Look at 19 Obesity Drugs: What a New Network Meta-Analysis Found
A large network meta-analysis in BMJ pooled 262 randomized trials to rank 19 obesity drugs by weight loss, side-effect burden, and cardiovascular outcomes. Here's what it found for semaglutide, retatrutide, and cagrilintide-based therapies, and why the benefit-harm tradeoff is more nuanced than a single weight-loss number suggests.
Aug 4, 2026Cagrilintide Acetate: Sourcing Considerations for Research Combinations
Cagrilintide almost always ships as an acetate salt, and it's increasingly ordered alongside GLP-1 and triple-agonist compounds for combination research. Here's what those two facts actually mean for sourcing and quality checks.
Aug 3, 2026REIMAGINE 2: New Phase 3 Data on Cagrilintide-Semaglutide in Type 2 Diabetes
REIMAGINE 2, a 2,713-participant phase 3 trial published this month, reports that the combined amylin/GLP-1 approach behind CagriSema produced a modestly larger reduction in HbA1c than semaglutide alone. Here's what the trial measured and what it adds to the research picture.
Aug 3, 2026New Research: MOTS-C Activates Metabolic Signaling but Blunts Stem-Cell Repair in Obesity Models
A newly published study on MOTS-C found something researchers weren't expecting: restoring the peptide's metabolic signaling in stressed stem cells didn't restore their repair capacity — it appeared to make it worse.
Aug 1, 2026A New Brainstem Atlas Maps the Neurons Behind Cagrilintide's Effects
Researchers built a 530,000-cell atlas of the brainstem across rats, mice, and macaques to trace exactly which neurons respond to cagrilintide — and found its effects run through a different hindbrain circuit than semaglutide's.
Jul 31, 2026The GLP-1 Research Landscape: From Gut Hormone to Multi-Agonist
GLP-1 research didn't start with weight management — it started with a question about why oral glucose triggers more insulin release than injected glucose. Here's how that question led to today's multi-agonist compounds.
Jul 26, 2026How to Choose a Research Peptide Supplier
Price is the easiest thing to compare between suppliers and the least useful. Here's a framework built around testing transparency, cold chain discipline, and sourcing — the variables that actually predict a bad batch.
Jul 24, 2026How to Read a Peptide Certificate of Analysis (COA)
A COA is only useful if you know what each section is actually reporting. Here's how to read the purity, identity, and mass-spec sections without taking the summary line on faith.
Jul 22, 2026Peptide Storage & Stability: A Practical Guide for Research Labs
Lyophilized peptides are stable for years at the right temperature and unstable within weeks at the wrong one. Here's what actually drives degradation, and how to store and reconstitute research peptides correctly.
Jul 20, 2026What Are Research Peptides? A Primer
Peptides sit in a specific chemical niche between small molecules and full proteins. Here's what defines them, how they're made, and why that manufacturing process matters for research quality.
Jul 18, 2026